Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.

@article{Flamiatos2017Cyclooxygenase2I,
  title={Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.},
  author={Jason F Flamiatos and Tomasz M Beer and Julie Nicole Graff and Kristine M. Eilers and Wei Tian and Harman S. Sekhon and Mark G Garzotto},
  journal={BJU international},
  year={2017},
  volume={119 5},
  pages={
          709-716
        }
}
OBJECTIVE To evaluate the biological effects of selective cyclooxygenase-2 inhibition on prostate tissue in patients undergoing radical prostatectomy (RP). PATIENTS AND METHODS Patients with localised prostate cancer were randomised to receive either celecoxib 400 mg twice daily or placebo for 4 weeks before RP. Specimens were analysed for levels of apoptosis, prostaglandins, and androgen receptor (AR). Effects on serum prostate-specific antigen (PSA) and postoperative opioid use were also… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES